KPMA Promote to Compose Consortium to Develop New Medicine

Published: 2001-11-23 06:59:00

Updated: 2001-11-23 06:59:00

KPMA put premise that the corporation model which Korean Pharmaceutical Industry can continue its development is the one progresses fair transaction and the other one with development capability of research and decided to concentrate their capability to materialize the corporation model.

KPMA...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK